Shinbaro (GCSB-5) / GC Biopharma, LG Chem - LARVOL DELTA

Pelubiprofen and Shinbaro: a therapeutic approach for osteoarthritis in a murine medial meniscus destabilization model. (PubMed, Front Pharmacol) - "Behavioral tests showed significant improvements in pain sensitivity and joint function with combination treatment. Shinbaro capsules + pelubiprofen effectively preserve chondrocytes, reduce inflammation, and alleviate osteoarthritis symptoms through synergistic mechanisms, making it a promising therapeutic strategy for osteoarthritis management."

Journal • Preclinical • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology • IL1B

Improvement of triceps muscle weakness in patients with cervical spondylotic myelopathy using Korean medicine therapy including shinbaro-2 pharmacopuncture: A CARE-compliant case series. (PubMed, Medicine (Baltimore)) - "The reported cases highlight KM treatment as a promising nonsurgical alternative for managing mild to moderate CSM, particularly in patients reluctant or unsuitable for surgery. KM treatments showed efficacy in improving pain, numbness, and muscular strength. Further rigorous studies are necessary to evaluate and confirm the broader applicability and effectiveness of KM approaches for CSM management."

Journal • CNS Disorders • Musculoskeletal Pain • Pain

Effects of Combined Shinbaro and Celecoxib in a Complete Freund's Adjuvant-Induced Inflammatory Pain Mouse Model. (PubMed, J Inflamm Res) - "Moreover, it decreased the expression of pro-inflammatory cytokines and mediators in the spinal cord by inhibiting spinal microglial activation. The combination of Shinbaro and celecoxib demonstrates significant anti-inflammatory and analgesic effects, suggesting its potential for managing inflammatory pain with fewer side effects than conventional therapies."

Journal • Preclinical • Immunology • Infectious Disease • Inflammation • Pain • Rheumatology

Synergistic attenuation of complete freund's adjuvant-induced inflammation in mice using shinbaro-pelubiprofen: a novel therapeutic complex. (PubMed, Mol Med) - "This combined effect highlights SBR-Pel's potential as an effective treatment for inflammatory diseases driven by heightened macrophage activity, while also minimizing side effects by reducing the Pel dosage."

Journal • Preclinical • Infectious Disease • Inflammation • Pain • CD68 • IL10 • MRC1 • TGFB1

Integrative Medicine Focusing on Ultrasound-Guided High-Dose Shinbaro 2 Pharmacopuncture for Acute Herniated Intervertebral Discs: A Case Report. (PubMed, Healthcare (Basel)) - "Notably, the changes observed during hospitalization were significant. This report suggests that ultrasound-guided high-dose Shinbaro 2 pharmacopuncture at Kambin's triangle significantly improves the pain, dysfunction, and quality of life in patients with an acute HIVD, demonstrating its potential usefulness among Korean medicine practitioners."

Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Repeated epidural delivery of Shinbaro2: effects on neural recovery, inflammation, and pain modulation in a rat model of lumbar spinal stenosis. (PubMed, Front Pharmacol) - "Our findings demonstrate that epidural Sh2 injection not only reduced inflammation but also improved locomotor function and pain in LSS model rats. Thus, Sh2 delivery via epidural injection has potential as an effective treatment option for LSS."

Journal • Preclinical • Immunology • Inflammation • Musculoskeletal Diseases • Neuralgia • Orthopedics • Pain

Systematic review and network meta-analysis on the efficacy and safety of parmacotherapy for hand osteoarthritis. (PubMed, PLoS One) - "In summary, GCSB-5 and CRx-102 exhibit efficacy in alleviating pain and stiffness in HOA, respectively. However, cautious interpretation of the results is advised. Tailored treatment decisions based on individual contexts are imperative."

Clinical • Journal • Retrospective data • Review • Immunology • Osteoarthritis • Pain • Rheumatology

Shinbaro2 enhances axonal extension beyond the glial scar for functional recovery in rats with contusive spinal cord injury. (PubMed, Biomed Pharmacother) - "Furthermore, Sh2 promoted the sprouting of serotonergic axons and the growth of neurofibrillary tangles, enhancing motor function recovery in SCI. These findings highlight the potential of Sh2 as an SCI therapeutic intervention, offering hope for neural and functional restoration in individuals with this debilitating condition."

Journal • Preclinical • CNS Disorders • Fibrosis • Inflammation • Orthopedics • Pain • NES • SOX9

Efficacy of herbal medicine in hand osteoarthritis: A narrative review. (PubMed, Curr Rheumatol Rev) - "Currently, the need for a low-risk alternative treatment in HOA patients is felt more than ever. There are reliable references relating to the safety of Korean red ginseng, GCSB-5, XLGB, and GS-GCu in these patients, although their efficacy was limited. Additionally, herbs like curcumin and Boswellia serrata have positively affected patients with knee osteoarthritis. However, there is a lack of strong evidence supporting their effectiveness in hand osteoarthritis (HOA). This emphasizes the potential benefits that these herbs may have for HOA patients."

Journal • Review • Immunology • Osteoarthritis • Pain • Rheumatology

Effects of the administration of Shinbaro 2 in a rat lumbar disk herniation model. (PubMed, Front Neurol) - "The results indicated that Shinbaro 2 administration restored spinal cord morphology and functions in the LDH model. Therefore, Shinbaro 2 exerted a protective effect in LDH via actions on inflammatory responses and disk degeneration, indicating that future research is warranted to assess the action mechanisms further and validate its effects."

Journal • Preclinical • Inflammation • Musculoskeletal Diseases • Oncology • Pain • IL1B • TNFA

Long-Term Follow-Up of Inpatients with Cervical Myelopathy Who Received Integrative Korean Medicine Treatment: A Retrospective Analysis and Questionnaire Survey Study. (PubMed, J Pain Res) - "At the follow-up, four patients experienced persistent pain and were undergoing treatment (19.1%), while 20 patients (95.8%) reported symptom improvement. From a long-term perspective, integrative KM treatment may help to reduce pain and improve function, and improve quality of life of CM patients."

Journal • Retrospective data • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

The Effectiveness of Megadose Shinbaro Pharmacopuncture for Patients With Chronic Shoulder Pain (clinicaltrials.gov) - P=N/A; N=36; Terminated; Sponsor: Jaseng Medical Foundation; N=80 ➔ 36; Trial completion date: Dec 2021 ➔ Jun 2021; Recruiting ➔ Terminated; Trial primary completion date: Dec 2021 ➔ Jun 2021; low participate rate

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Musculoskeletal Pain • Pain • Rheumatology

"$JKS JinkoSolar Announces Change to Senior Management https://t.co/00GE3gCSb5" (@stock_titan)

Long-Term Follow-Up of Inpatients with Failed Back Surgery Syndrome Who Received Integrative Korean Medicine Treatment: A Retrospective Analysis and Questionnaire Survey Study. (PubMed, J Clin Med) - "integrative KM treatment could effectively reduce pain, as well as improve function and health-related quality of life, in patients with FBSS."

Journal • Retrospective data • Back Pain • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Predictors of a placebo response in patients with hand osteoarthritis: post-hoc analysis of two randomized controlled trials. (PubMed, BMC Musculoskelet Disord) - "High levels of pain at baseline are predictive of a clinically meaningful placebo response in patients with hand OA. Further studies are needed to optimize and utilize the benefit of placebo responses in patients with hand OA."

Clinical • Journal • Retrospective data • Immunology • Osteoarthritis • Pain • Rheumatology

The Effectiveness of Megadose Shinbaro Pharmacopuncture for Patients With Chronic Shoulder Pain (clinicaltrials.gov) - P=N/A; N=80; Recruiting; Sponsor: Jaseng Medical Foundation; Trial completion date: Jul 2021 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Musculoskeletal Pain • Pain • Rheumatology

The Anti-Inflammatory Effects of Shinbaro3 Is Mediated by Downregulation of the TLR4 Signalling Pathway in LPS-Stimulated RAW 264.7 Macrophages. (PubMed, Mediators Inflamm) - "Three mechanisms explaining the effects of Shinbaro3 in RAW 264.7 cells were identified as follows: (1) inhibition of the extracellular signal-regulated kinase 1 and 2 (ERK1/2), stress-activated protein kinase (SAPK)/c-Jun N-terminal protein kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) pathways; (2) suppression of IκB kinase-α/β (IKK-α/β) phosphorylation and nuclear factor-kappa B (NF-κB) subunits in the NF-κB pathway, which are involved in MyD88-dependent signalling; and (3) downregulation of IFN-β mRNA expression via inhibition of interferon regulatory factor 3 (IRF3) and Janus-activated kinase 1 (JAK1)/signal transducer and activator of transcription 1 (STAT1) phosphorylation, which is involved in TRIF-dependent signalling. Shinbaro3 exerted anti-inflammatory effects in LPS-stimulated RAW 264.7 macrophage cells through modulation of the TLR4/MyD88 pathways, suggesting that Shinbaro3 is a novel anti-inflammatory therapeutic candidate in the field of..."

Journal • Biosimilar • Immunology

The Effect of GCSB-5 a New Herbal Medicine on Changes in Pain Behavior and Neuroglial Activation in a Rat Model of Lumbar Disc Herniation. (PubMed) - J Korean Neurosurg Soc - "These results indicate GCSB-5 reduces mechanical allodynia and downregulates neuroglial activity and the expressions of CGRP and TRPV1 in the spinal segments of a rat model of lumbar disc herniation."

Journal • Biosimilar • Pain

The Effectiveness of Megadose Shinbaro Pharmacopuncture for Patients With Chronic Shoulder Pain (clinicaltrials.gov) - P; N=80; Recruiting; Sponsor: Jaseng Medical Foundation

Clinical • New trial

Effects of SHINBARO2 on Rat Models of Lumbar Spinal Stenosis. (PubMed, Mediators Inflamm) - "In addition, brain-derived neurotrophic factor (BDNF), a potent promoter of neurite growth, and its downstream ERK signaling were also regulated by SHINBARO2. These findings suggest that the effect of SHINBARO2 might be associated in part with the anti-inflammation and pain control in LSS rat models."

Journal • Preclinical

Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials (ACR-ARHP 2019) - " This post hoc analysis of two double-blind, placebo-controlled, randomized trials investigating efficacy of GCSB-5 or diacerein in hand OA analyzed the efficacy of the placebo in patients with hand OA. This post hoc analysis of two prospective, double-blind, randomized, placebo-controlled studies showed that clinically meaningful response to placebo was observed in up to one third of patients with hand OA. This positive placebo response was associated with high pain level at baseline. Further researches are needed to optimize and utilize the benefit of placebo response in OA."

Clinical • Retrospective data

Survey of Integrative Treatment Practices of Korean Medicine Doctors for Cervical Disc Herniation: Preliminary Data for Clinical Practice Guidelines. (PubMed, Evid Based Complement Alternat Med) - "Shinbaro pharmacopuncture and Chungpa-jun, which are well-established herbal treatments supported by evidence, were considered to be of high importance in CDH treatment...This study is the first report to investigate current practice patterns and approach of Korean medicine doctors to CDH treatment. This data may be of significance to Korean medicine doctors in drawing clinical guidelines and conducting randomized controlled trials (RCTs) to generate high-level evidence on the effectiveness of nonsurgical integrative medicine treatments for CDH."

Clinical • Clinical guideline • Journal

The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study. (PubMed, Evid Based Complement Alternat Med) - "This study is registered in Clinical Research Information Service, Seoul National University Hospital Clinical Research Institute (IRB No. 1604-138-758)."

Clinical • Journal